Disclosed is an anti-human TIM-3 antibody against diseases associated with human TIM-3 expressing cells, which is capable of binding to the amino acid sequence of an extracellular domain of human TIM-3 or to the configuration of the extracellular domain and has high effector activity such as antibody-dependent cellular cytotoxicity (ADCC activity). Specifically disclosed are: a monoclonal antibody which is capable of binding to the amino acid sequence of an extracellular domain of human TIM-3 or to the configuration of the extracellular domain and exhibits ADCC activity, or a fragment of the antibody a hybridoma which is capable of producing the antibody a DNA which encodes the antibody a vector which comprises the DNA a transformant which is obtained by introducing the vector a method for producing an antibody or a fragment thereof using the hybridoma or the transformant and a therapeutic agent and a diagnostic agent, each of which contains the antibody or a fragment thereof as an active ingredient. Also specifically disclosed is an anti-human TIM-3 antibody exhibiting high ADCC activity, which is obtained by searching for an anti-human TIM-3 antibody that competes with the above-described monoclonal antibody or a fragment of the monoclonal antibody.Cette invention concerne un anticorps anti-TIM-3 humain dirigé contre les maladies associées aux cellules exprimant le TIM-3 humain, qui est capable de se lier à la séquence dacides aminés dun domaine extracellulaire du TIM-3 humain ou à la configuration du domaine extracellulaire et a une activité effectrice élevée telle quune cytotoxicité anticorps-dépendante (activité ADCC) élevée. Plus spécifiquement, cette invention concerne : un anticorps monoclonal qui est capable de se lier à la séquence dacides aminés dun domaine extracellulaire du TIM-3 humain ou à la configuration du domaine extracellulaire et manifeste une activité ADCC, ou un fragment dudit anticorps un hybridome qui est capable de produire lanticorps un
